Paris, France

Marco Alifano

USPTO Granted Patents = 2 

 

Average Co-Inventor Count = 2.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2013-2014

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Marco Alifano: Innovator in Cancer Treatment

Introduction

Marco Alifano is a prominent inventor based in Paris, France. He has made significant contributions to the field of oncology, particularly in the treatment and assessment of lung-related cancers. With a total of 2 patents, Alifano's work is paving the way for advancements in cancer care.

Latest Patents

Alifano's latest patents include innovative methods for the treatment and prognostic assessment of malignant pleural mesothelioma. This invention focuses on improving treatment options and prognostic evaluations for patients suffering from this aggressive form of cancer. Additionally, he has developed methods for the treatment, prognostic assessment, and staging of non-small cell lung cancer, which are crucial for enhancing diagnosis and treatment strategies.

Career Highlights

Throughout his career, Marco Alifano has worked with esteemed institutions such as the Institut National de la Santé et de la Recherche Médicale and Assistance Publique-Hôpitaux de Paris. His experience in these organizations has allowed him to collaborate with leading experts in the medical field and contribute to groundbreaking research.

Collaborations

Alifano has collaborated with various professionals, including his coworker Patricia Forgez, to further his research and innovations in cancer treatment.

Conclusion

Marco Alifano's contributions to cancer treatment through his patents and collaborations highlight his dedication to improving patient outcomes. His work continues to inspire advancements in the medical field, making a significant impact on cancer care.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…